Marble Harbor Investment Counsel LLC Sells 350 Shares of Eli Lilly and Company (NYSE:LLY)

Marble Harbor Investment Counsel LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 6,990 shares of the company’s stock after selling 350 shares during the quarter. Marble Harbor Investment Counsel LLC’s holdings in Eli Lilly and were worth $1,615,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. BlackRock Inc. lifted its position in Eli Lilly and by 3.1% in the second quarter. BlackRock Inc. now owns 60,927,657 shares of the company’s stock worth $13,984,117,000 after buying an additional 1,856,395 shares during the last quarter. State Street Corp increased its stake in Eli Lilly and by 1.3% in the second quarter. State Street Corp now owns 32,927,576 shares of the company’s stock worth $7,557,537,000 after purchasing an additional 421,475 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Eli Lilly and by 2.2% in the second quarter. Price T Rowe Associates Inc. MD now owns 26,739,216 shares of the company’s stock worth $6,137,184,000 after purchasing an additional 584,215 shares during the period. Geode Capital Management LLC increased its stake in Eli Lilly and by 4.2% in the second quarter. Geode Capital Management LLC now owns 13,964,273 shares of the company’s stock worth $3,196,763,000 after purchasing an additional 564,757 shares during the period. Finally, Jennison Associates LLC increased its stake in Eli Lilly and by 10.7% in the third quarter. Jennison Associates LLC now owns 9,864,516 shares of the company’s stock worth $2,279,196,000 after purchasing an additional 953,521 shares during the period. Institutional investors own 81.79% of the company’s stock.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 3,570 shares of the business’s stock in a transaction that occurred on Monday, December 27th. The stock was sold at an average price of $279.53, for a total value of $997,922.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 424,939 shares of company stock valued at $114,549,362 in the last ninety days. Corporate insiders own 0.13% of the company’s stock.

NYSE LLY traded down $3.76 during trading on Friday, hitting $245.91. The company’s stock had a trading volume of 26,431 shares, compared to its average volume of 2,775,004. The company has a debt-to-equity ratio of 1.95, a current ratio of 1.30 and a quick ratio of 1.02. The company has a market cap of $235.24 billion, a PE ratio of 38.06, a P/E/G ratio of 1.91 and a beta of 0.36. The business’s 50 day simple moving average is $260.85 and its 200-day simple moving average is $250.57. Eli Lilly and Company has a fifty-two week low of $178.58 and a fifty-two week high of $283.90.

Eli Lilly and (NYSE:LLY) last released its earnings results on Monday, October 25th. The company reported $1.94 EPS for the quarter, missing the Zacks’ consensus estimate of $1.98 by ($0.04). Eli Lilly and had a return on equity of 111.51% and a net margin of 21.52%. The firm had revenue of $6.77 billion for the quarter, compared to analyst estimates of $6.64 billion. During the same period last year, the firm earned $1.54 EPS. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. Analysts expect that Eli Lilly and Company will post 8.18 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 10th. Investors of record on Tuesday, February 15th will be issued a dividend of $0.98 per share. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.85. The ex-dividend date is Monday, February 14th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.59%. Eli Lilly and’s payout ratio is 51.83%.

A number of analysts have weighed in on the company. Truist Securities increased their target price on Eli Lilly and from $262.00 to $301.00 and gave the stock a “buy” rating in a research note on Wednesday, November 24th. Citigroup upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and raised their price target for the company from $210.00 to $265.00 in a research note on Wednesday, September 29th. They noted that the move was a valuation call. Mizuho raised their price target on Eli Lilly and from $272.00 to $302.00 in a research note on Wednesday, January 5th. Wells Fargo & Company raised their price target on Eli Lilly and from $270.00 to $280.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 4th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Eli Lilly and in a research note on Thursday, December 16th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $287.74.

About Eli Lilly and

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

Recommended Story: Learning About the VIX – Volatility Index

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.